Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Image of the MS-UK Helpline button graphic containing a link to the Helpline page

Image of the New Pathways magazine button graphic containing a link to the New Pathways magazine page


The effects of Cladribine for relapsing-remitting multiple sclerosis (RRMS) patients have been demonstrated to last for up to four years after treatment has started, according to the findings of a...

Regardless of whether the disease is in the progressive phase or not, patients with multiple sclerosis (MS) seem likely to experience relapses for the first time or relapse continuation between...

No correlation between interferon treatment and antidepressant use has been observed in the multiple sclerosis (MS) population, a large-scale study presented at the 68th AAN Annual Meeting...

Biogen has unveiled new Tecfidera research that, it says, reinforces its efficacy in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients and further supports its long-term, well...

The beneficial effects of oral propionate, an approved food additive, have been demonstrated in humans for the first time, according to a study presented at the American Academy of Neurology's...

A new study from NYU Langone Medical Center could provide hope for relief for some of the cognitive issues associated with multiple sclerosis.

In a randomised controlled trial, people with...

Results from a "highly promising pilot study" presented at the 68th annual American Academy of Neurology meeting in Canada have shown Lipoic acid is safe, well tolerated, and offers...

Results from new research suggest that maternal illness and pesticide-related environmental exposure contribute to risk of pediatric-onset multiple sclerosis (MS), whereas cesarean-section...

Once-daily Gilenya therapy is effective after four years of real-world clinical use among patients with relapsing remitting multiple sclerosis (RRMS), and has a safety profile that is “broadly...

Researchers from the United Kingdom have identified that men with gender identity disorder (GID) who took sex hormones to undergo a male-to-female conversion had a nearly seven-fold higher risk of...

Pages

Live Chat Software by Click4Assistance UK